Research Topic: antifungal susceptibility testing

Inferring fungal growth rates from optical density data

Scientists have developed a new mathematical method that allows doctors and lab technicians to measure fungal growth rates more accurately using simple optical density measurements. This approach doesn’t require expensive equipment or specialized knowledge, making it accessible to regular medical labs. The method could help doctors better assess how well antifungal drugs are working and detect resistant infections earlier.

Read More »

In Vitro Activity of Nitroxoline (5-Nitro-8-Hydroxyquinoline) Against Aspergillus Species

Researchers tested an old antibiotic called nitroxoline against Aspergillus fungi that cause serious infections in immunocompromised patients. The drug works by removing zinc that the fungus needs to survive. The study found that nitroxoline was very effective against all tested fungal strains, including those resistant to modern antifungal drugs, suggesting it could potentially be repurposed as a new treatment option.

Read More »

Evaluation of Antifungal Activity Against Candida albicans Isolates From HIV-Positive Patients with Oral Candidiasis in a Major Referral Hospital, West Java, Indonesia

This study examined fungal infections in HIV-positive patients’ mouths at an Indonesian hospital. Researchers identified which Candida species caused the infections and tested how well common antifungal medications worked against them. They found that while a specific antifungal drug (fluconazole) was effective in most cases, some infections showed resistance, suggesting the need for careful monitoring and personalized treatment approaches.

Read More »

In vitro activity of SF001: a next-generation polyene versus amphotericin B

This study tested a new antifungal drug called SF001 against a well-established antifungal called amphotericin B. Researchers tested both drugs against common fungal infections affecting vulnerable patients. SF001 was found to work as well as or better than amphotericin B, particularly against harder-to-treat Aspergillus fungi, while potentially causing fewer side effects.

Read More »
Scroll to Top